Buy & Sell Bristol-Myers Squibb Co (BMY) – Bristol-Myers Squibb Co Price Today
Aura AI Summary
Key Stats
- $117.46BMarket Cap
- HealthSector
- -12.52%3M Drawdown
- $153.40BEnterprise Value
- 4.38%Dividend Yield
- 92 daysTypical Hold Time
Bristol-Myers Squibb Co (BMY) is currently valued at a market capitalization of $117.46B, with an enterprise value of $153.40B. Over the past 52 weeks, Bristol-Myers Squibb Co has traded between a low of $42.6 and a high of $62.37, highlighting its annual price range. Over the past three months, Bristol-Myers Squibb Co has recorded a drawdown of -12.52%, reflecting recent price volatility. Bristol-Myers Squibb Co offers a dividend yield of 4.38%, with the most recent dividend of $0.63 paid on 02 Apr 26. On average, investors hold Bristol-Myers Squibb Co for approximately 92 days, indicating typical investor behavior on the platform.
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Most Recent News
Investors in Strategy Inc. may claim compensation over alleged misleading info in securities.
The Rosen Law Firm has announced an investigation into potential securities claims for shareholders of Strategy Inc. due to allegations that the company provided materially misleading business information. Investors who purchased Strategy securities ...

Ulta Beauty shares drop 20% YTD despite strong sales, creating a value buying opportunity.
Ulta Beauty's stock has fallen about 20% year-to-date, even though the company continues to show strong sales growth and gains in market share. This decline is largely due to investors rotating capital away from mega-cap tech stocks, which has left r...

Broadstone Net Lease rated strong buy for stable dividends, margin recovery, and portfolio strength.
Broadstone Net Lease (BNL) is rated a strong buy due to its margin recovery, diversified portfolio, and investment-grade balance sheet. The company has outperformed peers and the S&P 500 year-to-date, supported by steady industrial and retail demand ...
